Senior appointments at Teva and Johnson & Johnson

14 September 2012

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) has announced the appointment of Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head of business development Asia-Pacific. He will replace Moshe Manor as president and chief executive of Teva Asia-Pacific, who has decided to retire.

Currently serving as executive vice president, corporate business development at Teva, Prof Krinsky’s new appointment will be effective mid-October. He will be responsible for overseeing Teva’s generic and branded pharmaceuticals businesses in Japan and South Korea. Additionally, Professor Krinsky will manage Business Development for the Asia-Pacific region. He will continue to serve as a member of the Teva Executive Committee and will be located in Tokyo. Prof Krinsky’s former responsibilities as head of business development will become a part of the office of the CEO and remain a key focus for Teva.

J&J poaches Bayer executive

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK